The FDA approved Eli Lilly’s Mounjaro to reduce risks of heart attack, stroke, and cardiovascular death in high-risk adults with type 2 diabetes. This decision positions Mounjaro against Novo Nordisk’s Wegovy and Ozempic, which hold similar cardiovascular approvals.
The approval escalates competition in the lucrative GLP-1 market. Novo Nordisk’s oral version of Wegovy currently leads Lilly’s oral offering in weekly prescriptions.
Eli Lilly currently holds approximately 60% of the overall obesity market share. Novo Nordisk maintains the remaining 40% of the market.